<--GAT-->

TKI Persistence Rates at VHA Over Time

by U.S. Medicine

May 19, 2017

ELK GROVE, CA — How is chronic myeloid leukemia (CML) treated over an extended period at the VHA, including the use of tyrosine kinase inhibitor (TKI) therapy with imatinib, dasatinib and nilotinib?

A retrospective cohort study published in the journal Pharmacotherapy sought to answer that question.1

The study, led by California Northstate University researchers with participation from the South Texas Veterans Health Care System in San Antonio, involved 2,873 VHA beneficiaries aged 18-89 years who had at least one encounter at any of the about 150 VHA hospitals and 800 VHA clinics, had a diagnosis code for CML, and filled at least one prescription for imatinib, nilotinib or dasatinib between Oct. 1, 2001, and Sept. 30, 2010.

With primary study end points including change in TKI treatment, gaps in TKI treatment, TKI treatment persistence and patient survival, persistence for each line of treatment was defined as the time of continuous therapy, quantified by the number of days covered by the drug from treatment initiation until a 60-day gap in treatment was identified or a switch in treatment occurred.

Results indicated that, of the 2,873 patients receiving first-line TKI treatment, 586 (20.4%) switched to a different TKI, constituting second-line treatment. Overall, 245 patients (8.5%) were switched again to third-line treatment.

At the same time, only 4.4% of patients receiving first-line treatment experienced a gap in therapy of 60 or more days.

The study determined that first-line treatment persistence rates were 75%, 65% and 55% for the first, second and third years of treatment, respectively. The five-year survival with first-line treatment was calculated at 62%.

“In this national cohort of VHA patients, one-year persistence of first-line TKI treatment was similar to that in prior studies,” study authors concluded. “Five-year survival was comparable with that in other observational studies but was lower than that in prospective clinical trials. Persistence rates declined after the introduction of the new TKIs.”

  1. Kreys ED, Frei CR, Villarreal SM, Bollinger MJ, Jones X, Koeller JM. Evaluation of Long-Term Chronic Myeloid Leukemia Treatment Practices with Tyrosine Kinase Inhibitors in a National Cohort of Veterans. Pharmacotherapy. 2017 Mar;37(3):278-286. doi: 10.1002/phar.1893. Epub 2017 Feb 22. PubMed PMID: 28052354.

Related Articles

VHA Makes Progress in Improving Safety of Opioid Prescribing

VHA medical facilities should ensure that its providers are following three key opioid risk mitigation strategies, including conducting urine drug screening, a recent report recommended.

VA faces healthcare staffing shortages, barriers to hiring facility leaders

A facility-specific survey found that 138 of 140 VA facilities reported shortages of medical officers, with psychiatry and primary care positions being the most frequently listed.


U.S. Medicine Recommends


More From department of veterans affairs

Department of Veterans Affairs (VA)

VHA Makes Progress in Improving Safety of Opioid Prescribing

VHA medical facilities should ensure that its providers are following three key opioid risk mitigation strategies, including conducting urine drug screening, a recent report recommended.

Department of Veterans Affairs (VA)

VA faces healthcare staffing shortages, barriers to hiring facility leaders

A facility-specific survey found that 138 of 140 VA facilities reported shortages of medical officers, with psychiatry and primary care positions being the most frequently listed.

Department of Veterans Affairs (VA)

Veteran nephrologist labors to improve ESRD treatment at VA

When Terrence O’Neil, MD, retired as chief of nephrology at the James H. Quillen VAMC in Johnson City in December 2016, he left in his wake decades of work treating kidney disease—nearly 35 years in the Air Force and DoD, plus 11 more at VA.

Department of Veterans Affairs (VA)

Committee approves bill to provide agent orange benefits to ‘blue water’ vets

A long sought-after bill that would make it easier for Blue Water Navy veterans to receive Agent Orange benefits has been passed by a key House of Representatives committee.

Department of Veterans Affairs (VA)

Bill to Streamline, Expand VA’s Choice Program Signed Into Law

Legislation that would streamline VA’s community care programs into one program and expand VA’s caregiver program to veterans of all eras was signed into law earlier this month..

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up